Mobilized versus non-mobilized peripheral stem cell transplantation after high dose therapy for low grade nonhodgkin lymphoma. Effect on failure-free survival

A. Kessinger, Philip Jay Bierman, M. K. Cowles, J. R. Anderson, James Olen Armitage, M. R. Bishop, Julie Marie Vose

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Problem. Investigators have recently reported that intentional mobilization of progenitors into the circulation of cancer patients using myelosuppressive chemotherapy and/or hematopoietic growth factor is sometimes associated with an increased number of circulating malignant cells. Therefore, collections of mobilized autologous peripheral stem cells for transplantation could potentially contain more occult tumor cells than collections of non-mobilized cells. If these mobilized tumor cells were capable of restoring disease when reinfused to patients undergoing high dose therapy and peripheral stem cell transplantation (PSCT), then patients receiving mobilized PSCT would be at risk for a poorer failure-free survival than patients autografted with non-mobilized cells. Methods. To investigate this premise, the outcomes of all patients with low grade non-Hodgkin lymphoma (NHL) treated at a single institution before April 15, 1994 with high dose therapy and PSCT were reviewed. Results. Thirty-seven patients received non-mobilized peripheral stem cells at the time of autografting and 64 patients were transplanted with autologous cells that had been mobilized with hematopoietic growth factor. Following PSCT, no differences were found in the failure-free survival of patients who received mobilized versus non-mobilized cells for transplant. Conclusion. Growth factor mobilization did not influence the relapse rate for these patients with low grade NHL following peripheral stem cell autografting.

Original languageEnglish (US)
Pages (from-to)113-119
Number of pages7
JournalCancer Research Therapy and Control
Volume5
Issue number2
StatePublished - Jan 1 1998

Fingerprint

Peripheral Blood Stem Cell Transplantation
Non-Hodgkin's Lymphoma
Survival
Intercellular Signaling Peptides and Proteins
Therapeutics
Autologous Transplantation
Neoplasms
Research Personnel
Transplants
Recurrence
Drug Therapy

Keywords

  • Mobilization
  • Progenitor
  • Relapse-free survival
  • Tumor cell

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{98b42d02889b4819b35f4254f45404f4,
title = "Mobilized versus non-mobilized peripheral stem cell transplantation after high dose therapy for low grade nonhodgkin lymphoma. Effect on failure-free survival",
abstract = "Problem. Investigators have recently reported that intentional mobilization of progenitors into the circulation of cancer patients using myelosuppressive chemotherapy and/or hematopoietic growth factor is sometimes associated with an increased number of circulating malignant cells. Therefore, collections of mobilized autologous peripheral stem cells for transplantation could potentially contain more occult tumor cells than collections of non-mobilized cells. If these mobilized tumor cells were capable of restoring disease when reinfused to patients undergoing high dose therapy and peripheral stem cell transplantation (PSCT), then patients receiving mobilized PSCT would be at risk for a poorer failure-free survival than patients autografted with non-mobilized cells. Methods. To investigate this premise, the outcomes of all patients with low grade non-Hodgkin lymphoma (NHL) treated at a single institution before April 15, 1994 with high dose therapy and PSCT were reviewed. Results. Thirty-seven patients received non-mobilized peripheral stem cells at the time of autografting and 64 patients were transplanted with autologous cells that had been mobilized with hematopoietic growth factor. Following PSCT, no differences were found in the failure-free survival of patients who received mobilized versus non-mobilized cells for transplant. Conclusion. Growth factor mobilization did not influence the relapse rate for these patients with low grade NHL following peripheral stem cell autografting.",
keywords = "Mobilization, Progenitor, Relapse-free survival, Tumor cell",
author = "A. Kessinger and Bierman, {Philip Jay} and Cowles, {M. K.} and Anderson, {J. R.} and Armitage, {James Olen} and Bishop, {M. R.} and Vose, {Julie Marie}",
year = "1998",
month = "1",
day = "1",
language = "English (US)",
volume = "5",
pages = "113--119",
journal = "Cancer Research, Therapy and Control",
issn = "1064-0525",
publisher = "Harwood Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Mobilized versus non-mobilized peripheral stem cell transplantation after high dose therapy for low grade nonhodgkin lymphoma. Effect on failure-free survival

AU - Kessinger, A.

AU - Bierman, Philip Jay

AU - Cowles, M. K.

AU - Anderson, J. R.

AU - Armitage, James Olen

AU - Bishop, M. R.

AU - Vose, Julie Marie

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Problem. Investigators have recently reported that intentional mobilization of progenitors into the circulation of cancer patients using myelosuppressive chemotherapy and/or hematopoietic growth factor is sometimes associated with an increased number of circulating malignant cells. Therefore, collections of mobilized autologous peripheral stem cells for transplantation could potentially contain more occult tumor cells than collections of non-mobilized cells. If these mobilized tumor cells were capable of restoring disease when reinfused to patients undergoing high dose therapy and peripheral stem cell transplantation (PSCT), then patients receiving mobilized PSCT would be at risk for a poorer failure-free survival than patients autografted with non-mobilized cells. Methods. To investigate this premise, the outcomes of all patients with low grade non-Hodgkin lymphoma (NHL) treated at a single institution before April 15, 1994 with high dose therapy and PSCT were reviewed. Results. Thirty-seven patients received non-mobilized peripheral stem cells at the time of autografting and 64 patients were transplanted with autologous cells that had been mobilized with hematopoietic growth factor. Following PSCT, no differences were found in the failure-free survival of patients who received mobilized versus non-mobilized cells for transplant. Conclusion. Growth factor mobilization did not influence the relapse rate for these patients with low grade NHL following peripheral stem cell autografting.

AB - Problem. Investigators have recently reported that intentional mobilization of progenitors into the circulation of cancer patients using myelosuppressive chemotherapy and/or hematopoietic growth factor is sometimes associated with an increased number of circulating malignant cells. Therefore, collections of mobilized autologous peripheral stem cells for transplantation could potentially contain more occult tumor cells than collections of non-mobilized cells. If these mobilized tumor cells were capable of restoring disease when reinfused to patients undergoing high dose therapy and peripheral stem cell transplantation (PSCT), then patients receiving mobilized PSCT would be at risk for a poorer failure-free survival than patients autografted with non-mobilized cells. Methods. To investigate this premise, the outcomes of all patients with low grade non-Hodgkin lymphoma (NHL) treated at a single institution before April 15, 1994 with high dose therapy and PSCT were reviewed. Results. Thirty-seven patients received non-mobilized peripheral stem cells at the time of autografting and 64 patients were transplanted with autologous cells that had been mobilized with hematopoietic growth factor. Following PSCT, no differences were found in the failure-free survival of patients who received mobilized versus non-mobilized cells for transplant. Conclusion. Growth factor mobilization did not influence the relapse rate for these patients with low grade NHL following peripheral stem cell autografting.

KW - Mobilization

KW - Progenitor

KW - Relapse-free survival

KW - Tumor cell

UR - http://www.scopus.com/inward/record.url?scp=0031738968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031738968&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 113

EP - 119

JO - Cancer Research, Therapy and Control

JF - Cancer Research, Therapy and Control

SN - 1064-0525

IS - 2

ER -